Does aggressive statin therapy offer improved cholesterol-independent benefits compared to conventional statin treatment?

International Journal of Cardiology

Volumn 96, Issue 2, 2004, Pages 131-139

  Gupta, Sandeep ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Atorvastatin; C reactive protein; CRP; Inflammation; Pravastatin; Simvastatin; Statin

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ATHEROSCLEROSIS; DRUG EFFICACY; ENDOTHELIUM; HUMAN; INFLAMMATION; MORBIDITY; MORTALITY; PLAQUE FORMING CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RISK; THROMBOGENESIS; VASODILATATION;

EID: 3242777802     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.10.013     Document Type: Review

References (67)

1. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 335:1996;1001-1009
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339:1998;1349-1357
4. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 361:2003;1149-1158
5. Gould A.L., et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 97:1998;946-952
6. La Rosa J. Unresolved issues: unanswered questions. Eur. Heart J. Suppl. 1(Suppl. J):1999;J18-J23
7. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126
8. McLenachan J.M., Williams J.K., Fish R.D., Ganz P., Selwyn A.P. Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation. 84:1991;1273-1278
9. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 107:2003;363
10. Ridker P.M., Rifai N., Pfeffer M.A., et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol Recurrent Events (CARE) Investigators. Circulation. 100:1999;230-235
11. Albert M.A., Danielson E., Rifai N., et al. Effect of statin therapy on C-reactive protein levels. The pravastatin inflammatory/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 286:2001;64-70
12. Crea F., Monaco C., Lanza G.A., et al. Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clin. Cardiol. 25:2002;461-466
13. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolaemia (the CURVES study). Am. J. Cardiol. 81:1998;582-587
14. Chong P.H., Yim B.T. Rosuvastatin for the treatment of patients with hypercholesterolaemia. Ann. Pharmacother. 36:2002;93-101
15. Bolego C., Poli A., Cignarella A., et al. Novel statins: pharmacological and clinical results. Cardiovasc. Drugs Ther. 16:2002;251
16. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344:2001;1959-1965
17. Kinlay S., Timms T., Clark M., et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am. J. Cardiol. 89:2002;1205-1207
18. Lagrand W.K., Visser C.A., Hermens W.T., Niessen H.W., et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 100:1999;96-102
19. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347:2002;1557-1565
20. Lindahl B., Toss H., Siegbahn A., et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. N. Engl. J. Med. 343:2000;1139-1147
21. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 331:1994;417-424
22. Gupta S. Chronic infection in the aetiology of atherosclerosis - focus on Chlamydia pneumoniae. Atherosclerosis. 143:1999;1-6
23. Wilhelmsen L., Svärdsudd K., Korsan-Bengtsen, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N. Engl. J. Med. 311:1984;510-515
24. Bickel C., Rupprecht H.J., Blankenberg S., et al. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am. J. Cardiol. 89:2002;901-908
25. Gómez-Gerique, Ros E., Oliván J., et al. Effect of atorvastatin and benzafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis. 162:2002;245-251
26. Ansell B.J., Watson K.E., Weiss R.E., Fonarow G.C. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels a clinical investigation. Heart Dis. 5:2003;2-7
27. Casscells W., Hathorn B., David M., et al. Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis. Lancet. 347:1996;1447-1449
28. Stefanadis C., Diamantopoulos L., Dernellis J., et al. Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. J. Mol. Cell. Cardiol. 32:2000;43-52
29. Stefanadis C., Toutouzas K., Vavuranakis M., et al. Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques. Eur. Heart J. 23:2002;1664-1669
30. Romano M., Diomede L., Sironi M., et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. 80:2000;1095-1100
31. Riesen W.F., Engler H., Risch A., et al. Short-term effects of atorvastatin on C-reactive protein. Eur. Heart J. 23:2002;794-799
32. Joukhadar C., Klein N., Prinz M., et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolaemia. Thromb. Haemost. 85:2001;47-51
33. de Maat M.P., Kluft C., Hoogerbrugge N. No effect of pravastatin on C-reactive protein and fibrinogen level. Fibrinolysis Proteolysis. 13(Suppl. 1):1999;49-50
34. Horne B.D., Muhlestein J.B., Carlquist J.F., et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J. Am. Coll. Cardiol. 36:2000;1774-1780
35. Ridker P.M., et al. for the Cholesterol and Recurrent Events (CARE) Investigators Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844
36. Simon B.C., Cunningham L.D., Cohen R.A. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J. Clin. Invest. 86:1990;75-79
37. Vita J.A., Treasure C.B., Nabel E.G., et al. Coronary vasomotor responses to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497
38. Egashira K., Hirooka Y., Kai H., et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolaemia. Circulation. 89:1994;2519-2524
39. Cleland S.J., Sattar N., Petrie J.R., et al. Endothelial dysfunction as possible link between C-reactive protein levels and cardiovascular disease. Clin. Sci. 98:2000;531-535
40. Ngeh J., Anand V., Gupta S. Chlamydia pneumoniae and atherosclerosis - what we know and what we don't. Clin. Microbiol. Infect. 8:2002;2-13
41. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332:1995;481-487
42. Tan K.C.B., Chow W.S., Ham S.C.F., et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 87:2002;563-568
43. Drexler H., Hornig B. Endothelial dysfunction in human disease. J. Mol. Cell. Cardiol. 3:1999;51-60
44. Dobrucki L.W., Kalinowski L., Dobrucki I.T., Malinski T. Statin-stimulated nitric oxide release from endothelium. Med. Sci. Monit. 7:2001;622-627
45. Shishehbor M.H., Ronnier J.A., Brennan M.-L., et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 289:2003;1675-1680
46. Wiesbauer F., Kaun C., Zorn G., et al. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br. J. Pharmacol. 135:2002;284-292
47. Riesen W.F., Korte W., Engler H., Noseda G. Short-term effects of atorvastatin on coagulation and inflammation. Atherosclerosis. 3:2002;193. (Suppl.)
48. Crisby M., Nordin-Fredriksson G., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 103:2001;926-933
49. Ferrier K.E., Muhlmann M.H., Baguet J.-P., et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J. Am. Coll. Cardiol. 39:2002;1020-1025
50. Glorioso N., Troffa C., Filigheddu F., et al. Effect of the HMG-CoA reductase inhibitors on blood pressure with essential hypertension and primary hypercholesterolaemia. Hypertension. 34:1999;1281-1286
51. Abetel G., Poget P.N., Bonnabry J.P. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study. Schweiz. Med. Mochenschr. 128:1998;272-277
52. Prasad G.V.R., Ahmed A., Nash M.M., Zaltzman J.S. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney Int. 63:2003;360-364
53. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 103:2001;357-362
54. Paolisso G., Barbagallo M., Petrella G., et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis. 150:2000;121-127
55. Sparrow C.P., Burton C.A., Hernandez M., et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. 21:2001;115-121
56. Wilson S.H., Simari R.D., Best P.J., et al. Simvastatin preserves coronary endothelial function in hypercholesterolaemia in the absence of lipid lowering. Arterioscler. Thromb. Vasc. Biol. 21:2001;122-128
57. Baetta R., Camera M., Comparato C., et al. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid-lowering. Arterioscler. Thromb. Vasc. Biol. 22:2002;692-698
58. Kinlay S., et al. on behalf of the MIRACL Investigators Effect of atorvastatin on C-reactive protein in patients with acute coronary syndromes: a substudy of the MIRACL trial. 51st Annual Scientific Session of the American College of Cardiology, Atlanta, GA, USA, March 17-20, 2002. J. Am. Coll. Cardiol. vol. 39 (Suppl. A):2002;304A
59. Chan D.C., Watts G.J., Barrett P.H.R., et al. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin. Chem. 48:2002;877-883
60. Rodriguez M.M., Guerrero R.F. Increased levels of C-reactive protein in non-controlled type II diabetic subjects. J. Diabetes Complications. 13:1999;211-215
61. Kilpatrick E.S., Keevil B., Jagger C., et al. Determinants of raised C-reactive protein concentration in type 1 diabetes. QJM. 93:2000;231-236
62. Mullen M.J., Wright D., Donald A.E., et al. Atorvastatin but not L-arginine improves endothelial function in Type 1 diabetes mellitus: a double-blind study. J. Am. Coll. Cardiol. 36:2000;410-416
63. van de Ree M.A., Huisman V.M., Princen H.M.G., et al. Strong decrease of high-sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis. 166:2003;129-135
64. Wiklund O., Mattsson-Hultén L., Hurt-Camejo E., Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J. Int. Med. 251:2002;338-347
65. van Wissen S., Trip M.D., Tineke J.S., et al. Differential hs-CRP reduction in patients with familial hypercholesterolaemia treated with aggressive or conventional statin therapy. Atherosclerosis. 165:2002;361-366
66. Jialal I., Stein D., Balis D., et al. Effect of hydroxymethyl gluteryl coenzymes a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 103:2001;1933-1935
67. Athyros V.G., Papageorgiou A.A., Mercouris B.R., et al. The Greek atorvastatin on coronary heart disease evaluation study. Treatment with atorvastatin to the national cholesterol educational program versus usual care in secondary coronary heart disease prevention. Curr. Med. Res. Opin. 18(4):2002;220-228